Full Title
A Phase 1/2, First in Human Study on ODM212 in Subjects with Selected Advanced Solid TumoursPurpose
Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:
- Mesothelioma
- Epithelioid hemangioendothelioma
- Schwannoma
- Meningioma
- Renal cell cancer
- Bile duct cancer
- Head and neck cancer
- Lung cancer
- Colorectal cancer
- Liver cancer
- Prostate cancer
ODM-212 blocks a family of proteins called TEADs. These proteins help turn genes on or off. In healthy cells, TEADs help control normal growth. But in cancer cells, TEADs can get help from another protein that tells them to stay switched on all the time.
By blocking TEADs, ODM-212 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Contact
For more information or to see if you can join this study, please call 646-888-4226.
Protocol
25-275
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06725758
ClinicalTrials.gov